Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXT007 in Severe or Moderate Hemophilia A
NCT05987449Phase 2Recruiting
- Sponsor
- Roche
- Start
- Sep 2023
- Primary completion
- Dec 2033
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of zemocimig in hemophilia A, sponsored by Roche. Started Sep 2023; status: recruiting.
02
Drugs
zemocimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05987449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987449.